Quantcast

Latest Subcutaneous T-cell lymphoma Stories

2014-05-12 23:08:25

ResearchMoz.us includes new market research report "Peripheral T-Cell Lymphomas PTCL Clinical Trials Review, H1, 2014" to its huge collection of research reports. Get detail report with TOC @ http://www.researchmoz.us/peripheral-t-cell-lymphomas-ptcl-global-clinical-trials-review-h1-2014-report.html. Albany, New York (PRWEB) May 12, 2014 Researchmoz presents this most up-to-date research on"Peripheral T-Cell Lymphomas (PTCL) Global Clinical Trials Review, H1, 2014".The...

2014-03-25 23:31:01

Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too Raleigh, North Carolina (PRWEB) March 25, 2014 Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too. These findings have just been posted on the Non-Hodgkin’s Lymphoma Center at...

2014-02-24 23:26:06

Australian researchers say the combination of a psychiatry drug with a photosensitizer may work “synergistically” in patients with a certain kind of Non-Hodgkin’s Lymphoma. Raleigh, NC (PRWEB) February 24, 2014 The Non-Hodgkin’s Lymphoma Center is reporting on a new article in the Journal of Photochemistry and Photobiology detailing a promising new treatment for people with cutaneous T-cell lymphoma (CTCL), a variety of T-cell Non-Hodgkin’s Lymphoma involving the skin. Patients...

2012-06-18 05:43:06

(Ivanhoe Newswire) - NK/T-cell lymphoma is a very aggressive form of cancer, and currently has no effective treatment along with having a poor prognosis. This subtype of lymphoma is pretty rare in the United States, but is responsible for a large number of deaths in Asia, particularly China and Korea. A substantial proportion of NK/T-cell lymphomas harbor Janus Kinase 3 gene mutations. Patients with these lymphomas might benefit from treatment with a Janus Kinase inhibitor according to a...

2012-04-30 15:54:47

B cell lymphomas are a group of cancers of that originate in lymphoid tissue from B cells, the specialized immune cell type that produces antibodies. The development of B cell lymphoma is associated with several known genetic changes, including increased expression of MYC, a transcription factor that promotes cell growth and division. In this issue of the JCI, Andrei Thomas-Tikhonenko and his colleagues at the University of Pennsylvania in Philadelphia report on their studies to better...

2012-04-03 09:05:24

The product, once available in the clinic, could be the first to hit a pathway that drives multiple types of lymphoma, according to new research from Fox Chase. Scientists at Fox Chase Cancer Center in Philadelphia have come one step closer to developing the first treatment to target a key pathway in lymphoma. The new findings will be announced at the AACR Annual Meeting 2012 on Tuesday, April 3. "It's an exciting time to be involved in lymphoma treatment and research," says study...

2012-01-17 22:32:40

Promising findings on a novel combination treatment approach for a chronic type of skin lymphoma are being published today (embargoed for 4 pm) in JAMA's Archives of Dermatology by clinical researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine. The article outlines findings from a first-of-its-kind study showing that O6-benzylguanine is successful in treating cutaneous T-Cell lymphoma by enhancing the...

2011-08-19 16:10:00

WHITE PLAINS, N.Y., Aug. 19, 2011 /PRNewswire/ -- Today the Food and Drug Administration (FDA) approved Seattle Genetics' Adcetris to treat two types of rare blood cancers - Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL). (Logo: http://photos.prnewswire.com/prnh/20110215/NY48642LOGO ) The drug is approved for Hodgkin lymphoma patients after failure of a stem cell transplant or two chemotherapy treatments and for ALCL patients after failure of at least one multi-agent...

2010-08-04 00:30:00

SEATTLE, Aug. 4 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced it has filed for a Special Protocol Assessment ("SPA") with the U.S. Food and Drug Administration ("FDA") for the design of its new phase III trial of pixantrone for patients with relapsed or refractory aggressive B-Cell non-Hodgkin's lymphoma ("NHL"). In the filing, CTI proposed to the FDA that the randomized study will compare pixantrone plus rituximab against the current...


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related